약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)
Table. 1. Baseline characteristics of the study populations
2018 (N=128) 2019 (N=92) 2020 (N=90) 2018-2020 (N=310) p-value
Sex
Male 67(52.3%) 51(55.4%) 53(58.9%) 171(55.2%) 0.8072
Female 61(47.7%) 41(44.6%) 37(41.1%) 139(44.8%)
Age
20~49 32(25.0%) 21(22.8%) 16(17.8%) 69(22.3%) 0.4322
50~64 38(29.7%) 36(39.1%) 37(41.1%) 111(35.8%)
≥65 58(45.3%) 35(38.0%) 37(41.1%) 130(41.9%)
Insurance type
Health insurance 123(96.1%) 88(95.7%) 83(92.2%) 294(94.8%) 0.7741
Others 5(3.9%) 4(4.3%) 7(7.8%) 16(5.2%)
Type of healthcare facility
Tertiary general hospital 101(78.9%) 70(76.1%) 61(67.8%) 232(74.8%) 0.513
Others 27(21.1%) 22(23.9%) 29(32.2%) 78(25.2%)
Region
Seoul 67(52.3%) 43(46.7%) 44(48.9%) 154(49.7%) 0.826
Gyeonggi-do and Incheon 23(18.0%) 29(31.5%) 18(20.0%) 70(22.6%)
Non-Metropolitan 38(29.7%) 20(21.7%) 28(31.1%) 86(27.7%)
Chemotherapy
*CHOP-based therapy41(32.0%) 30(32.6%) 29(32.2%) 100(32.3%) <.0001
*ABVD therapy3(2.3%) 5(5.4%) 2(2.2%) 10(3.2%)
Daunorubicin and cytarabine-based therapy 2(1.6%) 2(2.2%) 0(0.0%) 4(1.3%)
Others 82(64.1%) 55(59.8%) 59(65.6%) 196(63.2%)
Tumor type
Hodgkin Lymphoma 4(3.1%) 5(5.4%) 4(4.4%) 13(4.2%) <.0001
Non-Hodgkin Lymphoma 64(50.0%) 50(54.3%) 45(50.0%) 159(51.3%)
Multiple myeloma 1(0.8%) 1(1.1%) 2(2.2%) 4(1.3%)
Leukemia 4(3.1%) 9(9.8%) 1(1.1%) 14(4.5%)
Others 55(43.0%) 27(29.3%) 38(42.2%) 120(38.7%)
Comorbidities
Diabetes 2(1.6%) 1(1.1%) 1(1.1%) 4(1.3%) 0.6505
Pulmonary disease 0(0.0%) 2(2.2%) 1(1.1%) 3(1.0%) 0.5673
Hypertension 4(3.1%) 1(1.1%) 1(1.1%) 6(1.9%) 1.0000
Dyslipidemia 1(0.8%) 2(2.2%) 0(0.0%) 3(1.0%) 1.0000
NCI comorbidity index
0 98(76.6%) 68(73.9%) 50(55.6%) 216(69.7%) 0.084
1 21(16.4%) 16(17.4%) 26(28.9%) 63(20.3%)
2 4(3.1%) 6(6.5%) 5(5.6%) 15(4.8%)
≥3 5(3.9%) 2(2.2%) 9(10.0%) 16(5.2%)

p-value was calculated using a chi-squared test

*CHOP (Cyclophosphamide, Doxorubicin, Vincrisine and Prednisolone)

*ABVD (Doroxubicin, Bleomycin, Vinblastine and Dacarbazine

Yakhak Hoeji 2024;68:311-9 https://doi.org/10.17480/psk.2024.68.5.311
© 2024 Yakhak Hoeji